The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the
Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer Cellares that will be used to supply patients in th
The 5th Gamma Delta T Cell Therapies Summit will bring together experts from big pharma, biotech and academia to delve into the details of gamma delta biology and its various subsets to off